Our research is focused on modifying effects of an isoflavone aglycones (IAs)-rich extract at a hormonally active dose of 150 mg/kg body weight/day on mammary and endometrial carcinogenesis in female Donryu rats. IA administered for 2 weeks in a phytoestrogen-low diet exerted estrogenic activity and induced cell proliferation in the uterus of ovariectomized rats. Furthermore, administration for 4 weeks resulted in elevation of cell proliferation in the mammary glands of 7,12-dimethylbenz [a] anthracene (DMBA)-treated animals. Forty weeks of postpubertal administration of IA to 5-week-old rats after initiation of mammary and endometrial carcinogenesis with DMBA and N-ethyl-N#-nitro-N-nitrosoguanidine (ENNG) caused significant increase of incidence and multiplicity of mammary adenocarcinoma, multiplicities of endometrial atypical hyperplasia, adenomatous polyps, and an increased trend of uterine adenocarcinomas. Liquid chromatography with tandem mass spectrometry and immunohistochemical analyses revealed significant elevation of tumorigenesis-related proteins such as S100 calcium-binding protein A8, kininogen 1, and annexins 1 and 2 in mammary adenocarcinomas and cadherin EGF LAG seven-pass G-type receptor 2, DEAD box polypeptide 1, and cysteine-and glycine-rich protein 1 in uterine proliferative lesions of IA-treated animals. Those changes are likely to be related to modulation of estrogen receptor (ER), AP1, nuclear factor-kappa B, and actin signaling pathways. Our results indicate that the postpubertal exposure of Donryu rats to IA at an estrogenic dose results in promotion of mammary and uterine carcinogenesis induced by DMBA and ENNG, which might be related to the activation of ERdependent signaling and alteration of the molecular tumor environment in the mammary gland and endometrium.
Isoflavone aglycones (IAs) found in soy products, like genistein, daidzein, and glycitein, are phytochemicals with various biological activities. Recently, more and more data have appeared demonstrating that the purported health benefits of soy isoflavones are quite variable, and the proposed protection offered by consumption is controversial (Banerjee et al., 2008; Xiao, 2008) . It has been shown that soy-derived isoflavones, which exhibit estrogen-like properties under certain experimental conditions, may stimulate the growth of existing estrogen-sensitive breast tumors (Messina and Loprinzi, 2001 ). Furthermore, it has been reported that isoflavones bind and transactivate estrogen receptors (ERs) (Jefferson and Newbold, 2000) . Nanomolar concentrations of genistein were further shown to induce acid ceramidase (ASAH1) transcription through a GPR30-dependent pertussis toxin-sensitive pathway that requires the activation of c-Src and extracellular signal-regulated kinase 1/2 (ERK1/2), thus stimulating breast cancer cell growth (Lucki and Sewer, 2011) .
On the basis of findings of a clinical trial performed using 179 postmenopausal women with intact uteri treated with 150 mg of isoflavones over a period of 5 years (Unfer et al., 2004a) , it was concluded that the long-term treatment (up to 5 years) with soy phytoestrogens (40-45% genistein [G] , 40-45% daidzein [D] , and 10-20% glycitein [Gl] ; G:D:Gl ¼ 2:2:1) was associated with an increased occurrence of endometrial hyperplasia. These findings call into question the safety of a long-term application of phytoestrogens with regard to the endometrium. However, in vivo data about the influence of soy isoflavones on uterine carcinogenesis are very limited. In rats, the incidences of spontaneous endometrial carcinomas are generally low, and only a few attempts at experimental induction of uterine adenocarcinoma by chemicals and/or hormones have been successful. Therefore, it has been difficult to assess the effects of any compound on uterine carcinogenesis in this animal species. To overcome this problem, a unique model for endometrial adenocarcinoma development has been established using the Donryu strain. A hormonal imbalance in this rat strain is associated with spontaneous endometrial adenocarcinoma development at 2 years of age (Maekawa et al., 1986; Nagaoka et al., 1990 Nagaoka et al., , 1994 . Furthermore, high yields of uterine cancers can be induced by intrauterine administration of N-ethyl-N#-nitro-N-nitrosoguanidine (ENNG) via the vagina (Yoshida et al., 1998) .
Older adults in Asia were reported to consume approximately 6-11 g of soy protein and 25-80 mg of isoflavones (expressed as aglycone equivalents) per day. In contrast, people in the United States and Europe consume on average less than 3 mg/day of isoflavones (Messina and Wood, 2008) . However, nowadays, many people are taking isoflavones as supplements. From the results of Unfer et al. (2004a) showing induction of uterine endometrial hyperplasia with an intake of 150 mg/day and the existing possibility that high concentrations of soy isoflavones might be hormonally active and exert adverse effects on hormonal carcinogenesis, in 2006, the Ministry of Health, Labour and Welfare of Japan has accepted 75 mg/day intake (acceptable daily intake [ADI] ) of soybean isoflavone to be the safe level for humans (Unfer et al., 2004a,b) .
It is of particular importance to detect whether hormonally active concentrations of isoflavones, especially IAs free of soy protein that are used now as supplements, might exert promoting effects on hormonal carcinogenesis. Therefore, the present study was carried out to investigate the influence of IA (genistein [52%], daidzein [42%] , and glycitein [6%]) at an estrogenic dose on mammary and uterine endothelial carcinogenesis after initiation using the Donryu rat model.
MATERIALS AND METHODS
Chemicals. 7,12-Dimethylbenz[a]anthracene (DMBA) was obtained from Tokyo Chemical Industry Co. Ltd, Tokyo, Japan, and ENNG from Nacalai Tesque, Kyoto, Japan. Polyethylene glycol (PEG) was from Wako Pharmaceutical, Osaka, Japan. Other chemicals were purchased from Sigma Chemical and were of analytical high performance liquid chromatography grade.
IA-rich extract. The IA-rich extract (SoyAct) was provided by Kikkoman Corporation (Noda City, Chiba, Japan). The extract was produced by fermentation of soy followed by ethanol/water extraction and purification and contained IAs genistein (52%), daidzein (42%), and glycitein (6%), and the total content of soy phytoestrogens in SoyAct was about 30%. The remaining 70% of the extract used in the present study was reported to contain saponin, protein, sugar, fat, moisture, ash, and fiber (Yamakoshi et al., 2000) . The protein component of the extract was composed of amino acids and peptides, which had molecular weights < 10,000 Da. The extract did not contain vitamin E.
Animals. A total of 68 female 4-week-old Donryu rats (Japan SLC, Shizuoka, Japan) were quarantined for 1 week before the start of the experiment. They were housed in an animal facility maintained on a 12-h (7:00-19:00) light/dark cycle, at a constant temperature of 23 ± 1°C and relative humidity of 44 ± 5%, and were given free access to tap water and NIH-07PLD diet (phytoestrogen-low diet; Oriental Yeast, Tokyo, Japan). NIH-07PLD diet contained crude protein, carbohydrate, fat, crude fiber, neutral detergent fiber, ash, amino acids, fatty acids, vitamins, and trace elements with no phytoestrogens. All experimental procedures were conducted following approval of the Animal Care and Use Committee of the Osaka City University Medical School. Guidelines set by the National Institute of Health and Public Health Service Policy on the Humane Use and Care of Laboratory Animals were followed at all times. Experiment 1. Ten 5-week-old female Donryu rats with normal estrous cycles were selected, and ovariectomy was performed. Absence of estrous cycles after the operation was confirmed with vaginal smears. Two weeks after the operation, rats were given 0.6% IA-rich extract (0.2% IA) in basal NIH-07PLD diet or only control diet only for a further 2 weeks. In this case, a rat (body weight 200 g) consumes IA in 15 g diet at a dose of 150 mg/kg body weight/day (100 times of ADI for human [the accepted by WHO safety factor in terms of ADI for rats is 100]), which is equal to about 1.5 mg/kg body weight/day intake by women with mean body weight 50 kg (ADI for human is 75 mg/day) (Lu, 1988) . Alternatively, the animal dose could be extrapolated to a human equivalent dose by using the body surface area normalization method (mg/m 2 conversion) (Freireich et al., 1966; Reagan-Shaw et al., 2008) . In such conversion, extrapolating from human to rat involves multiplying the human dose by 6.16 (Km human/Km animal ¼ 37/6). If using this extrapolation, the animal dose 150 mg/kg body weight/day used in the present study will be equal to about 24 mg/kg body weight/day intake by human.
All animals were checked for general condition at least once a day. Body weights were measured once a week. At sacrifice, uterine weights were measured to detect estrogenic activity of 0.2% IA. Furthermore, histological examination of the uterus, mammary gland, liver, kidneys, spleen, adrenals, and thymus was performed.
Experiment 2. Five 5-week-old female rats received 50 mg/kg DMBA in sesame oil/kg body weight (ig), and another five were given an equivalent volume of sesame oil (~0.5 ml/rat, ig). Rats were administered IA-rich extract at a dose of 0.6% (0.2% IA) in NIH-07PLD diet or basal diet only for 4 weeks starting from the day of DMBA injection. Animals were killed by deep anesthesia with diethyl ether, and skin and mammary gland samples were obtained and fixed in 10% phosphate-buffered formalin. Representative sections of each mammary gland were routinely processed for pathological examination and bromodeoxyuridine (BrdU) immunohistochemistry. In addition, uterus, liver, kidneys, spleen, adrenals, thymus, and weights were measured. Experiment 3. At 5 weeks of age, 48 female Donryu rats were selected and divided into three groups. Donryu rats' pubertal development starts soon after weaning, from about postnatal day 35. Rats were inspected daily for vaginal opening since onset of puberty is defined as the age (in days) at which vaginal opening occurred. To initiate mammary carcinogenesis, 5-week-old rats in IA-treated and initiation control groups (21 rats per group) were given a single dose of DMBA by ig (50 mg/kg body weight) at the commencement of the experiment. ENNG (10 mg/kg body weight) in PEG was administered via the vagina using a stainless catheter on experimental days 7 and 11 to initiate uterine carcinogenesis. In the control group, six animals received sesame oil by ig and PEG via the vagina as the vehicle. Animals were administered the IArich extract at a dose of 0.6% (0.2% IA) in NIH-07PLD basal diet or control basal diet for 40 weeks starting from the commencement of the experiment. All animals were checked for general condition at least once a day. Body weights were measured once a week. The estrous cycle status was ascertained at 3-month intervals with vaginal smears throughout the study. Age-related persistent estrus followed by anovulation in Donryu rats was reported to be started at 5 months of age, and its incidence was markedly increased until 8 months (Nagaoka et al., 2000) . Multiplicity and volume of mammary tumors were examined every week, and location of every nodule was recorded and diagnosed after final histopathological examination. Mammary gland tumor volume being calculated as tumor length/2 3 (width/2) 2 and expressed as cm cytological features, such as number of mitoses or nuclear enlargement and the presence or absence of invasion of the stroma and neighboring tissues.
Complete necropsies were done on all surviving animals at week 40 after the initiation with DMBA (45 weeks of age). The following organs were removed and weighed: uterus, skin with mammary glands, ovaries, liver, pituitary, and adrenals. The ovaries, uteri, vaginas, and other representative organs were fixed in 10% phosphate-buffered formalin solution and then routinely processed for histopathological examination. Animals found dead or killed when moribund were also autopsied and sampled for histopathology. Each uterus was dissected into about 12 specimens in cross-section, and proliferative endometrial lesions were classified into 3°of atypical hyperplasias, adenocarcinomas, stromal, and adenomatous polyps using the categories described in previous report (Nagaoka et al., 1994) .
LC-MS/MS, iTRAQ labeling, and quantification of protein expression. Proteome analysis was performed on a DiNa-AI nano LC System (KYA Technologies, Tokyo, Japan) coupled to a QSTAR Elite hybrid mass spectrometer (AB Sciex, Concord, Canada) through a NanoSpray ion source (AB Sciex) as described previously (Kakehashi et al., 2011) . Each sample was run for 150 min.
Because of the difficulties of collection of normal mammary gland and uterine endometrium tissues by microdissection, it was decided to use the pooled samples for proteome analysis. The lysis buffer was chosen and adjusted specially to use with formalin-fixed and paraffin embedded (FFPE) sections according to the recently published method (Klein et al., 2011) . Furthermore, we have performed comparative analysis of frozen tissue and FFPE sections Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of different animal tissues, which demonstrated high concordance of results. Duplicate pooled samples from microdissected and/or needle dissected 10% phosphate-buffered formalin-fixed mammary adenocarcinomas (DMBA, ENNG: 1 rat, DMBA, ENNG/0.2% IA: 6 rats), uterine adenocarcinomas and severe atypical hyperplasias (DMBA, ENNG: 3 rats, DMBA, ENNG/0.2% IA: 6 rats) and normal-appearing mammary gland (DMBA, ENNG: 20 rats, DMBA, ENNG/0.2% IA: 20 rats), or endometrium (DMBA, ENNG: 20 rats, DMBA, ENNG/0.2% IA: 20 rats) from rats in initiation control group and group administered 0.2% IA after the DMBA and ENNG treatment were prepared in 20mM Tris-HCl buffer, pH 8, with 0.002% Zwittergent, treated with heat at 90°C for 90 min (spin down every 20 min), digested with trypsin at 37°C for 16-18 h, and centrifuged at 12,350 3 g for 1 min. Protein concentrations were measured with BCA Protein Assay Kit (Pierce, IL). Each pooled sample contained 10 lg protein. Thereafter, labeling was performed with 4-plex iTRAQ reagents according to standard procedures (Gluckmann et al., 2007) . Pooled samples were labeled as described below: iTRAQ isobaric reagents 114, normal mammary gland or endometrium in DMBA, ENNG/0.2% IA-treated groups; 115, mammary adenocarcinomas or uterine adenocarcinomas and severe atypical hyperplasias in DMBA, ENNG/0.2% IA-treated groups; 116, normal mammary gland or endometrium in DMBA, ENNG treated groups; and 117, mammary adenocarcinomas or uterine adenocarcinomas and severe atypical hyperplasias in DMBA, ENNG control groups. MS/MS data were searched against the Swiss Protein database (RAT) using ProteinPilot software (version 2.0; AB Sciex) with trypsin set as the digestion enzyme and methyl methanethiosulfonate as the cysteine modification. The search results were further processed by ProteinPilot software using the Paragon Algorithm for redundant hits removing and comparative quantitation, resulting in the minimal set of justifiable identified proteins. Each sample was measured three times, and all reported data were used at 95% confidence cutoff limit created by ProteinPilot software. The same program was used to remove the bias for proteins expressed at very low levels. Protein ratios with a p value less than 0.05 were considered reliable. Previously, SDs of the protein ratio, which stem from technical variation, were reported to be less than 0.3 in 90% of iTRAQ experimental runs (Song et al., 2008) . In this experiment, expression changes greater than 1.3-fold or less than 0.769-fold in normalized expression levels were decided to be outside the range of technical variability.
Ingenuity Pathway and Bioinformatic analyses. To assign biological significance to differentially labeled proteins, to identify networks of interacting proteins, functional groups, and pathways, and to determine whether the protein candidates were known plasma proteins, secreted or membrane proteins or were associated mammary gland or uterus, cancer, the Ingenuity program (Ingenuity Systems, Mountain View, CA) was utilized. Proteins known to be associated with cancer biology were prioritized for further validation. Bioinformatic analysis of gene promoters encoding proteins with altered expression was performed using PROMOSER and TFSEARCH Internet databases for identification of common transcriptional factors that may be driving the expression changes.
Immunohistochemical examination. For the evaluation of cellular proliferation in the rat uterus and mammary glands, BrdU (experiment 1) and PCNA (experiment 2) immunohistochemistry were performed as previously described (Kinoshita et al., 2003) . In experiments 1 and 2, all 12 specimens in cross-section of uterus from all rats were subjected to the analysis. BrdU and PCNA indices were assessed as the number of positive nuclei per 1000 cells.
Paraffin sections containing preneoplastic and neoplastic lesions as well as normal mammary gland and uterus tissues were used for comparison and stained using standard immunohistochemical methods. Goat polyclonal antibodies against annexin 1, kininogen 1 and cadherin, EGF LAG seven-pass G-type receptor 2 (Santa Cruz Biotechnology Inc.), rabbit polyclonal antibodies against annexin 2, DEAD box polypeptide 1, destrin, cysteine-and glycine-rich protein 1 and S100 calcium-binding protein A8 (Abcam Co., Japan), ER-alpha (ER-a) (Santa Cruz Biotechnology Inc.), and ER-beta (ER-b) (Millipore, Upstate) were employed for immunohistochemical validation of the results of the proteome analysis in the mammary gland and uterus (Supplementary data). Immunohistochemical procedures were optimized by testing different antigen retrieval methods and negative controls.
Statistical analysis. Statistical analysis was performed using the StatLight-2000(C) program (Yukms Corp., Japan) or the IBM SPSS Statistics 19 Software (IBM). Fisher's exact probability test or the v 2 -test and log-rank test were used to compare the tumor incidence of histopathological lesions. Homogeneity of variance was tested by the F-test. Differences in mean values for tumor multiplicities and volumes between the initiation control and the IAtreated groups were evaluated by the two-tailed Student's t-test when variance was homogeneous and the two-tailed Aspin-Welch t-test when variance was heterogeneous. Survival curves were calculated using the Kaplan-Meier method, and differences in survival curves were assessed with the log-rank test. p values less than 0.05 were considered significant. For analysis of protein expression, ProteinPilot 2.0 Software was employed.
RESULTS

Short-Term Studies (Experiments 1 and 2)
Estrogenic effect of 0.2% IA. After ovariectomy in experiment 1, 0.2% IA administration resulted in persistent estrus evident on examination of vaginal smears (data not shown). Mean relative uterus weight was significantly elevated in 0.2% IA-administered ovariectomized rats (0.58 ± 0.13%, p < 0.005) as compared with control rats (0.32 ± 0.04%), thus demonstrating estrogenic activity of the 150 mg/kg body weight/day dose of IA in the rat uterus (data not shown). After confirmation of the estrogenic effect of 0.2% IA, this dose was applied in experiments 2 and 3 to study the modifying effects of a hormonal dose of IA on rat endometrial and mammary carcinogenesis. In short-term experiments, no changes in body weight were observed in IA-treated rats as compared with the initiation control groups. Long-term Study (Experiment 3) General observations. Four animals in the initiation control group and six animals in 0.2% IA-administered group died during the study. The causes in the initiation control group were malignant lymphoma/leukemia (three rats) and zymbal gland tumor (one rat). No animals died from uterine or mammary gland cancers. On the other hand, in the 0.2% IAtreated group, causes of death were mammary adenocarcinomas (three rats), uterine adenocarcinoma (one rat), and bleeding from large necrotic mammary tumors (two rats). Three IA-treated rats featured metastasis of mammary adenocarcinomas in the lung. Significant increase of mammary tumor volumes measured macroscopically was observed in the group treated with IA compared with the initiation control group (from week 29 to week 32) (Fig. 1C) . However, due to the sudden growth of benign tumors in the mammary gland of the initiation control group starting from week 32 up to the termination of the experiment, a significant decrease of total mammary tumor volume was finally observed in the IA-treated rats.
The body weights of 0.2% IA-treated rats were significantly depressed starting from the first week (p < 0.05) of IA application up to the termination of the experiment at week 40 (p < 0.0001) compared with the initiation control group (Fig. 1D) . Body weights of IA-treated animals demonstrated 10% reduction from week 10 to 20, 16% reduction at week 30, and 19% reduction at the termination at week 40. Food intake did not differ between groups. However, water intake was significantly depressed by IA application, starting from the first week and up to week 40.
No significant differences in uterus, liver, kidneys, spleen, heart, thymus pituitary, and adrenals weights were observed (data not shown).
Survival curves (experiment 3). At week 15, the first rat from the initiation control group was found dead with a lymphoma/leukemia. The number of surviving IA-administered animals started quickly to decrease at week 21, mostly due to the development of mammary and uterine tumors, which were not found in the initiation control group (Fig. 1E) . A trend for decrease in survival rate of IA-treated rats, however, without significant difference compared with the initiation control group, was found at final sacrifice.
Histopathological findings in the mammary gland. The results for macroscopically evident mammary gland tumor incidences, multiplicities and volumes, as well as histopathological analysis and representative pictures are presented in Table 1 and Figures 1A-C and 2A (a-d) . In the group administered 0.2% IA, significant increases of mammary gland adenocarcinoma incidence (week 33-36) and multiplicity (week 32-36) as compared with the initiation control rats were observed (Figs. 1A and 1B) . The onset of tumor development in rats administered IA (adenocarcinomas: week 15) was earlier than that of initiation control rats (benign tumor: week 19) (Figs. 1A and 1B) . Unexpectedly, due to the sudden development of benign tumors in the mammary gland of the DMBA, ENNG control group starting from week 32, a significant decrease of total benign tumor incidence and multiplicity was finally detected in the IA-treated group (Figs. 1A and 1B) .
Histopathological analysis of the mammary gland tumors at termination of the experiment demonstrated significant elevation of adenocarcinoma incidence (p < 0.05) and multiplicity (p < 0.05) in IA-administered rats. On the other hand, significant decrease of fibroadenoma (p < 0.05) and total tumors multiplicities in the group fed IA after initiation was found (Table 1) . Furthermore, a trend for decrease was detected for the incidence of benign tumors in the group of animals treated with IA (Table 1) .
Histopathological findings in the uterus. The results of histopathological analysis of rat uteri are presented in Table 1 and Figure 2A (e-l). At necropsy, the uteri in IA-treated rats demonstrated increased hemorrhage, dilatation, and higher numbers of nodules macroscopically (data not shown). Histopathologically, most of the animals in the initiation control and IA-treated groups demonstrated various proliferative lesions in the uteri, with a sequence of changes from atypical hyperplasias to adenocarcinomas ( Fig. 2A [e-h] ) as well as development of stromal and adenomatous polyps ( Fig. 2A [i-l]) . A significant increase in the multiplicities of total atypical hyperplasia (HPL) (mild, medium, and severe) and total endometrial proliferative lesions (adenocarcinoma þ atypical HPL) was found in the uteri of IA-administered animals (Table 1) . A trend for increase was also observed for the incidence and multiplicity of endometrial adenocarcinomas in the IA-treated group as compared with the initiation control rats. Moreover, a significant elevation of multiplicities of adenomatous polyps was detected in the uteri of the IAadministered group (Table 1 and Fig. 2A [i-l] ).
Alterations of protein expression in mammary adenocarcinomas. The results of the QSTAR Elite LC-MS/MS and Ingenuity Pathway analyses (IPA) of the mammary gland adenocarcinomas compared with the normal-appearing mammary gland tissue of rats from initiation control and IA-treated animals are presented in Table 2 .
Interestingly, only in the adenocarcinomas of IA-treated animals, significant overexpression of S100 calcium-binding protein A8 (S100A8) (12.38-fold), involved in cell cycle progression and angiogenesis, as well as kininogen 1 (KNG1) (5.1-fold), which is an F-actin-associated protein participating in phosphorylation and activation of epidermal growth factor receptor (EGFR), was found (Table 2) . Furthermore, as
FIG. 1. (A)
Incidence and (B) multiplicity of mammary tumors in female Donryu rats in experiment 3, (C) volume of mammary tumors examined every week during the experiment, (D) body weights, and (E) survival curves of Donryu rats. Significant increase of mammary adenocarcinoma incidence and multiplicity in DMBA, ENNG/0.2% IA-administered rats, and on the other hand, decrease of benign tumors multiplicity was found. Furthermore, early elevation of mammary adenocarcinomas incidence, multiplicity, and tumors volume in IA-administered rats was observed from week 15.
ISOFLAVONE EFFECTS ON HORMONAL CARCINOGENESIS
compared with the protein spectrum of initiation control rats, in adenocarcinomas of IA-administered group, an elevation of expression was observed for proteins participating in cellular assembly and organization pathways, including annexin 1 (ANXA1), annexin 2 (ANXA2) and cytokeratin 8 (CK8) (fusion of liposome, aggregation of cellular membrane, organization of filaments), cytokeratin 5 (CK5), capping protein (actin) muscle Z-line, alpha 2 (CAPZA2) and transgelin (TAGLN) (organization of F-actin), fibronectin (FN1), tubulin beta 2C (TUBB2C), LMNA (detachment of desmin filament, morphology of nucleus), and thymopoietin (TMPO) (assembly of inner nuclear membrane). Moreover, elevated expression of cellular chaperone heat shock-related endoplasmic reticulum protein 29 (ERP29) involved in NRF2-mediated oxidative stress response, poly(A)-binding protein cytoplasmic 1 (PABPC1) promoting ribosome recruitment and translation initiation was detected. In addition, in IA-treated rats, significant downregulation of decorin (DCN), an anti-tumorigenic protein capable of suppressing the growth of various tumor cell lines and interaction with EGFR and TGF-b, was obvious (Table 2) .
Proteome analysis of the normal mammary gland tissue of rats treated with IA when compared with the normal mammary gland of initiated control rats demonstrated upregulation of CK8, PDIA3, and HSP90AB1 and downregulation of DCN, similar to that observed in adenocarcinomas of IA-administered animals, which might be indicative of occurred cellular stress and activation of ER signaling.
Alteration of protein expression in endometrial proliferative lesions. Data from proteome and IPA of the uterine proliferative lesions compared with protein expression of the normal endometrium of rats 40 weeks after initiation or after treatment with IA are presented in Table 2 .
As compared with the protein spectrum of the initiation control rats endometrial proliferative lesions, in IA-administered animals, a significant increase of flamingo cadherin, EGF LAG seven-pass G-type receptor 2 (CELSR2), a receptor involved in contact-mediated communication with cadherin and EGF-like domains, cysteine-and glycine-rich protein 1 (CSRP1) and destrin (DSTN), two proteins participating in Rho-dependent organization of F-actin, RNA helicase DEAD box polypeptide 1 (DDX1), and downregulation of decorin, as in mammary adenocarcinomas, was found (Table 2 ).
In the normal endometrium of IA-administered rats, upregulation of CK8, 19, TAGLN, histones HIST2H2AA3, HIST1H2BH, HIST1H1D, and desmin (DES) and downregulation of DCN as compared with the normal-appearing endometrium of rats in initiation control group were detected (data not shown). 
FIG. 2. (A)
Representative histopathological changes in the mammary gland (a-d) and uteri (e-l) observed in both initiation control and IA-treated animals (hematoxylin and eosin). Moderate atypical hyperplasia is composed of an increased number of glands under the lining epithelium (e and f). Well-differentiated endometrial adenocarcinoma (AdCa) (g and h). Atypical glands in the endometrium are irregularly proliferating and invading the muscle layer (arrow). Stromal polyp (i and g) and adenomatous polyp (k and l) (magnification 320 [a, c, e, g, i, and k) and 3200 (b, d, f, h, j, and l]). (B) Immunohistochemistry for ANX1 (a and b), ANX2 (c and d), KNG1 (e and f), S100A8 (g and h), ER-a (i and j), and ER-b (k and l) in the mammary gland and (C) immunohistochemistry for CELSR2 (a and b), CSRP1 (c and d), DDX1 (e and f), destrin (g and h), ER-a (i and j), and ER-b (k and l) in uterine adenocarcinoma and severe hyperplasia of initiation control (a, c, e, g, i, and k) and IA-administered rats (b, d, f, h, j, and l) (magnification 3400). Note increased nuclear expression of ER-a and ER-b in both mammary adenocarcinomas and uterine proliferative lesions of rats treated with IA. Significant cytoplasmic and membranous overexpression of ANX1 and particularly ANX2, cytoplasmic elevation of KNG1, and an increase of S100A8 in inflammatory cells were observed in the mammary AdCa of IA-treated animals. Furthermore, nuclear elevation of CELSR2, CSRP1, and DDX1 (arrows) and cytoplasmic overexpression of destrin were evident in uterine proliferative lesions of rats administered IA. Orthogonal antibody-based validation. To confirm proteome analysis results, we examined the protein expression in tumor tissue by immunohistochemistry. We focused our validation efforts on proteins for which antibodies with the prerequisite specificity were available. In the mammary gland adenocarcinomas, four proteins that met these criteria were ANXA1, ANXA2, KNG1, and S100A8, all of which were found to be overexpressed in 100% of mammary adenocarcinomas of IA-treated rats with low to undetectable expression in initiation control group (Fig. 2B [a-h]) . In all adenocarcinomas of IA-administered animals, ANXA1 was present in tumor cells in a cytoplasmic distribution, whereas membranous or extracellular staining was observed for ANXA2 and KNG1. Strong positive staining for S100A8 was found in the inflammatory cells, in adenocarcinomas of IA-treated rats.
ISOFLAVONE EFFECTS ON HORMONAL CARCINOGENESIS
In 100% of uterine adenocarcinomas and 90% of atypical hyperplasias of the IA-administered group, CELSR2, CSRP1, and DDX1 were found in both nuclear and cytoplasmic compartments, whereas in all proliferative lesions of initiation Notes. C, cytoplasm; N, nucleus; PM, plasma membrane; ES, extracellular space; CS, cytoskeleton; TR, transcriptional regulator; CC, cell cycle; E, enzyme; K, kinase; T, transporter; OP, oxidative phosphorylation; M, metabolism; TMR, transmembrane receptor; TRL, translation; NEO, nuclear envelope organization; PF, protein folding; EMO, extracellular matrix organization; G, G protein; VT, vesicle transport; RP, mRNA processing; SEC, secretion; DM, dendrite morphogenesis; NSD, nervous system development; U, unknown; O, other; -, no change of protein expression; FC, fold change as compared with normal-appearing tissue area.
control animals CELSR2, CSRP1 expression was only cytoplasmic, and DDX1 nuclear expression was less prominent (Fig. 2C [a-h]) . Furthermore, increased levels of DSTN in the cytoplasm were observed in all adenocarcinomas and 88% of atypical hyperplasias in the IA-treated group.
Additionally, to check the estrogenic response, we performed the immunohistochemical examination of ). In all mammary and uterine adenocarcinomas and 91% of uterine atypical hyperplasias of IA-treated animals, predominant nuclear overexpression of ER-a and to lesser extent ER-b was detected. Furthermore, in proliferative lesions of rats in the IA group, a significant increase of ER-a and ER-b of cytoplasmic localization was found.
Bioinformatic and IPA analyses. Analyses of the promoter regions of genes encoding proteins with altered expression in mammary adenocarcinomas and uterine proliferative lesions of initiation and IA-treated groups demonstrated that common transcriptional factors, which may be driving the expression changes, are AP1 and nuclear factor-kappa B (NF-jB) (Figs. 3A and 3B; data not shown). Most of the differentially expressed proteins detected by QSTAR Elite MS/MS were targets for these transcriptional factors, containing binding sites and participated in reorganization of F-actin. Furthermore, IPA functional analysis indicated that in both mammary and endometrial adenocarcinomas of IA-administered rats, upregulated or downregulated proteins were related to cancer, reproductive and endocrine system disorders, cellular assembly and organization, cellular movement, inflammatory response, cellular growth and proliferation, DNA replication, recombination, and repair pathways (data not shown).
DISCUSSION
The present study demonstrated that postpubertal exposure to IA-rich extract at a dose of 150 mg/kg body weight/day possessed estrogenic activity, induced cell proliferation in the mammary gland and endometrium, altered the molecular tumor environment, and promoted mammary and uterine carcinogenesis in Donryu rats induced by DMBA and ENNG. Furthermore, in IA-treated rats, the development of mammary adenocarcinomas metastasizing to the lung was observed, which were totally lacking in the initiation control rats. A decrease of body weight and adipose deposition in IAtreated rats observed in the present study was possibly due to antilipogenic effects described earlier in mice (Naaz et al., 2003) . Furthermore, this study demonstrated that starting from week 32, in the initiation control group, sudden development of mammary gland benign tumors but not adenocarcinomas FIG. 3 . Signaling pathways involving differentially expressed proteins in mammary gland adenocarcinomas (A) and uterine proliferative lesions (B) of rats treated with DMBA and ENNG and administered 0.2% IA controlled by AP1 and NF-jB transcriptional factors (compared initiation control and IA-treated groups). Note strong overexpression of KNG1 and S100A8 in mammary adenocarcinomas and various F-actin-associated proteins in the uterine proliferative lesions.
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occurs. This fact might be of importance when analyzing the effects of IA treatments of different duration on mammary carcinogenesis in animal models.
Soy isoflavones are known to become distributed to a wide variety of tissues as IAs and conjugates, and the IA is thought to be a mixture of bioactive molecules (Gu et al., 2005) . Furthermore, IA was previously found to be absorbed in higher amounts than glycoside forms in humans , what might explain in part the detrimental effects observed in the present study. The timing of exposure to isoflavones is thought to be a critical component for an effect on breast cancer risk. Thus, it was reported that neonatal genistein treatment exerted its chemoprevention action by acting directly to enhance maturation of terminal ductal structures and by altering the endocrine system to reduce cell proliferation in the mammary gland (Lamartiniere et al., 1995) . In contrast, as detected in the present study, the postpubertal exposure of Donryu rats to hormonally active dose of IA increased cell proliferation and promoted mammary and uterine carcinogenesis in a two-step carcinogenesis model.
Utero and mammary trophic effects of IA were previously suggested to be due to potentiation of signaling via ER-a and ER-b (Messina and Wood, 2008) , similar transactivation capacity in reporter gene transfected cells being observed with either receptor, the estrogen response element and a reporter gene (Messina and Wood, 2008) . The effects of isoflavones, therefore, are thought to be dependent on the dose of exposure. ''Physiological'' concentrations are known as those achieved in the serum of persons consuming the commonly recommended daily dose of isoflavones of 50-100 mg (Wuttke et al., 2007) . In the majority of in vitro studies, in which MCF-7 cells derived from human mammary cancer were analyzed, physiological concentrations of soy extracts and pure isoflavones stimulated growth (Gutendorf and Westendorf, 2001; Harris et al., 2005; Hsieh et al., 1998; Wang et al., 1996) . Furthermore, in a human breast cancer cell line, hormonally active concentrations of soy isoflavones were shown to suppress the detoxification of reactive catechol metabolites of 17beta-estradiol (E2) and inhibit the activity of catechol-Omethyltransferase (COMT), an enzyme involved in the metabolic activation and inactivation of E2 that may lead to promotion of mammary carcinogenesis (Lehmann et al., 2008) .
In line with these results, we demonstrated that an estrogenic dose of an IA-rich extract manufactured as a soy isoflavone supplement with genistein as the main aglycone activated ER-a or ER-b and downstream AP1 and NF-jB transcriptional factors, furthermore potentiating F-actin signaling in mammary and uterine adenocarcinomas. Even in the normal-appearing mammary gland and endometrium, IA administration was associated with the induction of several cytoskeletal proteins, such as CK8, 19, and TAGLN, and the suppression of DCN expression, similar to that in adenocarcinomas, which might be related to activation of ER signaling. Previously, reorganization of F-actin regulated by Rho family proteins was shown to lead to the activation of a number of transcriptional factors, such as AP1 and NF-jB, with associated alteration of expression of various genes, and finally induction of proliferation, invasion, and metastasis by different cancers (Wang et al., 2010) . Furthermore, supporting our data, NF-jB activation was recently detected in endometrial carcinogenesis and was suggested to be a novel target of oncogenic KRAS (Mizumoto et al., 2011) .
To our knowledge, we present here the first evidence of conspicuous elevation of S100A8 and KNG1 and downregulation of DCN, an anti-tumorigenic protein capable of suppressing the growth of various tumor cell lines and interaction with EGFR and TGF-b, in mammary adenocarcinomas of IA-treated rats. The findings support the conclusion that IA at an estrogenic dose promotes invasiveness of mammary tumors. Activation of EGF receptor was previously reported to be an important factor for initiation and progression of malignancies, including breast cancers (Milanezi et al., 2008) .
Supporting our results, increase of calcium-binding protein S100A8, which promotes tubulin polymerization, phagocyte migration, infiltration of granulocytes and upregulates transcription of genes that are under the control of NF-jB, has been reported in human breast ductal carcinoma in situ (Carlsson et al., 2005; Cross et al., 2005; Seth et al., 2003) . Furthermore, detailed analysis of proximal promoter regions of human calprotectin, a heterodimer of S100A8 and S100A9, revealed common binding sites for distinct transcription factors, such as AP1, NF-jB, and C/EBP, suggesting a relation to S100A8 elevation observed in the present study (Gebhardt et al., 2006) . KNG1 is known as an extracellular matrix F-actinassociated protein and inhibitor of thiol proteases participating in phosphorylation and activation of EGFR and from the present data might become a possible biomarker associated with promotion of mammary carcinogenesis and possibly invasiveness of mammary adenocarcinomas. Previously, its active peptide bradykinin, which increases phosphorylation of mouse Mapk1 protein involved in the mutant mouse Egfr gene in mouse Mef cells (Thomas et al., 2006; Wunderer et al., 1990) , has been detected in malignant ovarian, colon, and breast carcinomas but not in benign tumors.
Induction of CELSR2, CSRP1, and DSTN, which participate in Rho-dependent organization of F-actin, as well as RNA helicase DDX1, was here observed in the endometrial adenocarcinomas of IA-administered rats, and downregulation of DCN might be suggested to be related to the promotion of endometrial carcinogenesis by a hormonally active dose of IA. Furthermore, the shift in CELSR2 and CSRP1 localization to the nuclei as well as increase of DDX1 nuclear expression might indicate their participation in ER-dependent signaling. Under normal conditions, the flamingo cadherins, such as CELSR2, specific functions of which have yet to be determined, are known to be located at the plasma membrane and act as receptors involved in contact-mediated communication, ISOFLAVONE EFFECTS ON HORMONAL CARCINOGENESIS with cadherin domains acting as homophilic binding regions and EGF-like domains involved in cell adhesion and receptorligand interactions (Nakayama et al., 1998) .
In conclusion, in the present study, long-term postpubertal treatment of Donryu rats with IA at a dose of 150 mg/kg body weight exerted promoting effects on mammary and uterine endometrial carcinogenesis after initiation with DMBA and ENNG. Furthermore, activation of ERs, AP1 and NF-jB, and F-actin signaling was apparent with the hormonally active dose of the IA-rich extract, associated with rise in ER-a and ER-b nuclear localization, which might have caused elevation of cell proliferation, leading to the promotion and progression to more malignant lesions.
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